Critical Contrast: Aevi Genomic Medicine (GNMX) and Windtree Therapeutics (WINT)

Aevi Genomic Medicine (NASDAQ: GNMX) and Windtree Therapeutics (OTCMKTS:WINT) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, institutional ownership, analyst recommendations, dividends, earnings, profitability and risk.

Analyst Recommendations

This is a summary of current ratings and target prices for Aevi Genomic Medicine and Windtree Therapeutics, as provided by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Aevi Genomic Medicine 0 1 1 0 2.50
Windtree Therapeutics 0 1 0 0 2.00

Aevi Genomic Medicine currently has a consensus price target of $4.25, indicating a potential upside of 226.92%. Given Aevi Genomic Medicine’s stronger consensus rating and higher probable upside, analysts clearly believe Aevi Genomic Medicine is more favorable than Windtree Therapeutics.

Insider & Institutional Ownership

16.8% of Aevi Genomic Medicine shares are held by institutional investors. Comparatively, 0.3% of Windtree Therapeutics shares are held by institutional investors. 15.2% of Aevi Genomic Medicine shares are held by company insiders. Comparatively, 0.8% of Windtree Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Volatility & Risk

Aevi Genomic Medicine has a beta of 0.4, indicating that its share price is 60% less volatile than the S&P 500. Comparatively, Windtree Therapeutics has a beta of 1.76, indicating that its share price is 76% more volatile than the S&P 500.


This table compares Aevi Genomic Medicine and Windtree Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Aevi Genomic Medicine N/A -163.88% -130.14%
Windtree Therapeutics -1,205.47% N/A -345.52%

Valuation & Earnings

This table compares Aevi Genomic Medicine and Windtree Therapeutics’ top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Aevi Genomic Medicine N/A N/A -$41.90 million ($0.96) -1.35
Windtree Therapeutics $2.04 million 8.09 -$39.49 million ($71.83) 0.00

Windtree Therapeutics has higher revenue and earnings than Aevi Genomic Medicine. Aevi Genomic Medicine is trading at a lower price-to-earnings ratio than Windtree Therapeutics, indicating that it is currently the more affordable of the two stocks.


Aevi Genomic Medicine beats Windtree Therapeutics on 8 of the 13 factors compared between the two stocks.

Aevi Genomic Medicine Company Profile

Aevi Genomic Medicine, Inc., a clinical stage biopharmaceutical company, researches and develops novel therapies for pediatric onset and life-altering diseases in the United States. Its lead product candidates include AEVI-001, a glutamatergic neuromodulator, which is in Phase II/III SAGA trial for a genetically-defined subset of adolescent attention deficit hyperactivity disorder patients with specific mutations in their metabotropic glutamate receptor gene network; and AEVI-002, an anti-light monoclonal antibody that is in Phase I clinical trial for use in severe pediatric onset crohn’s disease. The company was formerly known as Medgenics, Inc. and changed its name to Aevi Genomic Medicine, Inc. in December 2016. Aevi Genomic Medicine, Inc. was founded in 2000 and is based in Wayne, Pennsylvania.

Windtree Therapeutics Company Profile

Windtree Therapeutics, Inc., formerly Discovery Laboratories, Inc., is a biotechnology company. The Company is focused on developing KL4 surfactant therapies for respiratory diseases and other potential applications. The Company operates through the research and development of products focused on surfactant therapies for respiratory disorders and diseases, and the manufacture and commercial sales of approved products segment. The Company’s technology platform includes a synthetic, peptide-containing surfactant (KL4 surfactant) that is structurally similar to endogenous pulmonary surfactant, and drug delivery technologies being developed to enable non-invasive administration of aerosolized KL4 surfactant. The Company’s core development program, AEROSURF (lucinactant for inhalation), is focused on improving the management of respiratory distress syndrome (RDS) in premature infants, a respiratory condition that can result in long-term respiratory problems, developmental delay and death.

Receive News & Ratings for Aevi Genomic Medicine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aevi Genomic Medicine and related companies with's FREE daily email newsletter.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit